@misc{Krawczyk_Katarzyna_Detection_2016,
 author={Krawczyk, Katarzyna},
 address={Kraków},
 howpublished={online},
 year={2016},
 school={Uniwersytet Jagielloński. Collegium Medicum. Wydział Lekarski.},
 language={pol},
 abstract={The analysis of 226 patients, treated with MCL in Hematology Clinic UJCM between 1992-2013, was conducted. 1st line chemotherapy regimens were: CHOP +/- R in 50%, FC+/-R in 23% and intensive induction treatment with cytarabine in 20%. Consolidation with radioimmunotherapy was administered in 34 cases, in 47 – HDT/ASCT. MRD was regularly assessed with flow cytometry in 46 patients. In 75% molecular was detected. Pre-emptive treatment was conducted in 25 cases. 20 of these patients, were treated intensively in the first line, with HDT/ASCT consolidation. Fist line treatment results were: ORR in 71,68%, SD in 5,31%. MCL was refractory in 24,78 % of cases. Median PFS was 28,78 months and median OS 49,9. Treatment results were similar to data from multicenter trials. Survival depended on: type of 1st line treatment and risk factors – MPI. MRD follow-up with flow cytometry is effective in molecular relapse detection, its implementation has an impact on survival in MCL patients. Pre-emptive therapy is effective method of MRD (-) re-achieving (ORR 80%). The use of pre-emptive therapy has a strong impact on OS and PFS among MCL patients, especially in subgroup after consolidation with HDT/ASCT (5-cio letnie OS 100%, vs.65%, PFS 100% vs.45%).},
 title={Detection of early relapse with flow cytometry and its impact on effectiveness of pre-emptive treatment in patients with mantle cell lymphoma},
 type={Praca doktorska},
 keywords={mantle cell lymphoma, minimal residual disease, pre-emptive therapy, molecular relapse},
}